FDA Posts Liver Failure Report Linked to Lilly's Foundayo
A single liver failure case in the FDA adverse event database briefly knocked Lilly stock; analysts and Lilly say one report is not a safety signal.
May 6, 2026 · 2 min read
The FDA's adverse event database now lists a liver failure report tied to Foundayo, Eli Lilly's recently launched oral GLP-1 (orforglipron). The report briefly pulled Lilly shares down roughly 3% on Monday before recovering, after the company and Wall Street analysts pushed back that one case in a database is not a safety signal.
What happened
The FDA Adverse Event Reporting System (FAERS) entry, filed April 30, describes a liver failure event in a 56-year-old male, with the underlying event reportedly occurring on or before April 15. The agency separately asked Lilly for additional safety data on Foundayo, which the company says it has provided.
Lilly's response was direct: a spokesperson stated the event was "not reasonably related" to the drug, citing more than 11,000 patients dosed across seven Phase 3 trials with no meaningful liver safety signal.
For context, FAERS already contains hepatic failure reports across the GLP-1 class — roughly 30 cases linked to Mounjaro, 33 to Ozempic, 15 to Wegovy, and 2 to Zepbound. RBC Capital Markets analysts urged investors not to overreact, writing that "one liver case does not make a signal."
Why it matters
FAERS is a pharmacovigilance tool, not a causation database. Anyone — patient, doctor, lawyer — can submit a report, and an entry only means a clinician or patient associated the drug with an adverse event in time, not that the drug caused it. That's why the FDA explicitly warns against using raw FAERS counts to compare drug safety.
Still, Foundayo is a high-profile launch — the first oral pill in the GLP-1 class designed for outpatient daily dosing — and the FDA's request for additional data signals it will be tracked closely. For patients on Foundayo, current labeling does not flag liver injury as a known risk, and the GLP-1 side effects guide summarizes the established safety profile.
What to watch
Whether more FAERS reports accumulate over the next quarter is the relevant signal — single cases don't move regulatory action, clusters do. Lilly's next earnings call (August) will likely include updated post-marketing surveillance numbers, and any FDA label change would come from a formal safety review rather than a single FAERS entry. For now, Foundayo prescribing continues unchanged.
Sources
Sources